@techreport{oai:mie-u.repo.nii.ac.jp:00011741,
 author = {片山, 直之 and KATAYAMA, NAOYUKI},
 month = {May},
 note = {application/pdf, t(3;4)(p13;q12)を持つ骨髄増殖性腫瘍において、PDGFRAと融合する第7番目遺伝子FOXP1を同定した。CALR遺伝子変異を伴う本態性血小板血症では、血小板数はJAK2変異を伴うETのそれより高値を示したものの、血栓症の頻度が低かった。60歳以下の急性骨髄性白血病の予後中間群では、IL-2受容体apha鎖発現は独立した予後因子である。単球はMCP-1/CCR2の経路を介して膵臓に侵入し、星細胞へ分化する。遺伝子改変T細胞は養子細胞移入後も宿主内で機能を保持しながら生存する。, We identified the seventh partner gene of PDGFRA, FOXP1, in a patient with myeloproliferative neoplasm with eosinophilia, harboring the chromosomal abnormality t(3;4)(p13;q12). Platelet counts of CALR-mutated patients tended to be higher than those of JAK2-mutated patients. However, the occurrence of a thrombotic event was more frequently associated with CALR-mutated patients than with JAK2-mutated patients. The expression of IL-2R alpha on acute myeloid leukemia cells is a poor prognostic factor of acute myeloid leukemia patients ≦ 60 years old. Monocytes in the peripheral blood migrate into the pancreas at least partially through the MCP-1/CCR2 pathway and differentiate into pancreatic stellate cells. When transferred into hosts, tumor antigen-specific T cell receptor gene-engineered T cells retain the ex vivo antigen-specific tumor reactivity to persist for long period., 2013年度～2015年度科学研究費補助金(基盤研究(C))研究成果報告書, 25461413},
 title = {リンパ球造血異常の解析からの骨髄増殖性腫瘍の病態解明へのアプローチ},
 year = {2016},
 yomi = {カタヤマ, ナオユキ}
}